Search

Search Constraints

You searched for: Author/Creator Lebwohl, M.

Search Results

12. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. (23rd August 2021)

13. Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. (14th July 2021)

14. Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. (1st October 2021)

16. FRI0272 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES. (13th June 2020)

17. Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials. (4th September 2017)

18. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. (28th March 2019)

20. Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up. (1st May 2015)